1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for
Study
1.2.3. Key Market
Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key
Market Segmentations
3.3. Overview of Key
Market Players
3.4. Overview of Key
Regions/Countries
3.5. Overview of Market
Drivers, Challenges, Trends
4.
Global Next Generation Cancer Diagnostics Market Outlook
4.1. Market Size &
Forecast
4.1.1. By Value
4.2. Market Share &
Forecast
4.2.1. By
Technology (Next-generation Sequencing, qPCR & Multiplexing, Lab-on- a-
chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA
Microarrays)
4.2.2. By
Application (Biomarker Development, CTC Analysis, Proteomic Analysis,
Epigenetic Analysis, Genetic Analysis)
4.2.3. By
Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer,
Others)
4.2.4. By
Region
4.2.5. By Company (2022)
4.3. Market Map
4.3.1. By Technology
4.3.2. By Application
4.3.3. By Cancer Type
4.3.4. By Region
5.
Asia Pacific Next Generation Cancer Diagnostics Market
Outlook
5.1. Market Size &
Forecast
5.1.1. By Value
5.2. Market Share &
Forecast
5.2.1. By
Technology
5.2.2. By
Application
5.2.3. By Cancer Type
5.2.4. By Country
5.3. Asia Pacific:
Country Analysis
5.3.1. China Next
Generation Cancer Diagnostics Market Outlook
5.3.1.1.
Market Size & Forecast
5.3.1.1.1.
By Value
5.3.1.2.
Market Share & Forecast
5.3.1.2.1.
By Technology
5.3.1.2.2.
By Application
5.3.1.2.3.
By Cancer Type
5.3.2. India Next
Generation Cancer Diagnostics Market Outlook
5.3.2.1.
Market Size & Forecast
5.3.2.1.1.
By Value
5.3.2.2.
Market Share & Forecast
5.3.2.2.1.
By Technology
5.3.2.2.2.
By Application
5.3.2.2.3.
By Cancer Type
5.3.3. Australia Next
Generation Cancer Diagnostics Market Outlook
5.3.3.1.
Market Size & Forecast
5.3.3.1.1.
By Value
5.3.3.2.
Market Share & Forecast
5.3.3.2.1.
By Technology
5.3.3.2.2.
By Application
5.3.3.2.3.
By Cancer Type
5.3.4. Japan Next
Generation Cancer Diagnostics Market Outlook
5.3.4.1.
Market Size & Forecast
5.3.4.1.1.
By Value
5.3.4.2.
Market Share & Forecast
5.3.4.2.1.
By Technology
5.3.4.2.2.
By Application
5.3.4.2.3.
By Cancer Type
5.3.5. South Korea Next
Generation Cancer Diagnostics Market Outlook
5.3.5.1.
Market Size & Forecast
5.3.5.1.1.
By Value
5.3.5.2.
Market Share & Forecast
5.3.5.2.1.
By Technology
5.3.5.2.2.
By Application
5.3.5.2.3.
By Cancer Type
6.
Europe Next Generation Cancer Diagnostics Market Outlook
6.1. Market Size &
Forecast
6.1.1. By Value
6.2. Market Share &
Forecast
6.2.1.
By Technology
6.2.2.
By Application
6.2.3. By Cancer Type
6.2.4.
By Country
6.3. Europe: Country
Analysis
6.3.1. France Next
Generation Cancer Diagnostics Market Outlook
6.3.1.1.
Market Size & Forecast
6.3.1.1.1.
By Value
6.3.1.2.
Market Share & Forecast
6.3.1.2.1.
By Technology
6.3.1.2.2.
By Application
6.3.1.2.3.
By Cancer Type
6.3.2. Germany Next
Generation Cancer Diagnostics Market Outlook
6.3.2.1.
Market Size & Forecast
6.3.2.1.1.
By Value
6.3.2.2.
Market Share & Forecast
6.3.2.2.1.
By Technology
6.3.2.2.2.
By Application
6.3.2.2.3.
By Cancer Type
6.3.3. Spain Next
Generation Cancer Diagnostics Market Outlook
6.3.3.1.
Market Size & Forecast
6.3.3.1.1.
By Value
6.3.3.2.
Market Share & Forecast
6.3.3.2.1.
By Technology
6.3.3.2.2.
By Application
6.3.3.2.3.
By Cancer Type
6.3.4. Italy Next
Generation Cancer Diagnostics Market Outlook
6.3.4.1.
Market Size & Forecast
6.3.4.1.1.
By Value
6.3.4.2.
Market Share & Forecast
6.3.4.2.1.
By Technology
6.3.4.2.2.
By Application
6.3.4.2.3.
By Cancer Type
6.3.5. United Kingdom Next
Generation Cancer Diagnostics Market Outlook
6.3.5.1.
Market Size & Forecast
6.3.5.1.1.
By Value
6.3.5.2.
Market Share & Forecast
6.3.5.2.1.
By Technology
6.3.5.2.2.
By Application
6.3.5.2.3.
By Cancer Type
7.
North America Next Generation Cancer Diagnostics Market
Outlook
7.1. Market Size &
Forecast
7.1.1. By Value
7.2. Market Share &
Forecast
7.2.1.
By Technology
7.2.2.
By Application
7.2.3. By Cancer Type
7.2.4. By Country
7.3. North America:
Country Analysis
7.3.1. United States Next
Generation Cancer Diagnostics Market Outlook
7.3.1.1.
Market Size & Forecast
7.3.1.1.1.
By Value
7.3.1.2.
Market Share & Forecast
7.3.1.2.1.
By Technology
7.3.1.2.2.
By Application
7.3.1.2.3.
By Cancer Type
7.3.2. Mexico Next
Generation Cancer Diagnostics Market Outlook
7.3.2.1.
Market Size & Forecast
7.3.2.1.1.
By Value
7.3.2.2.
Market Share & Forecast
7.3.2.2.1.
By Technology
7.3.2.2.2.
By Application
7.3.2.2.3.
By Cancer Type
7.3.3. Canada Next
Generation Cancer Diagnostics Market Outlook
7.3.3.1.
Market Size & Forecast
7.3.3.1.1.
By Value
7.3.3.2.
Market Share & Forecast
7.3.3.2.1.
By Technology
7.3.3.2.2.
By Application
7.3.3.2.3.
By Cancer Type
8.
South America Next Generation Cancer Diagnostics Market
Outlook
8.1. Market Size &
Forecast
8.1.1. By Value
8.2. Market Share &
Forecast
8.2.1.
By Technology
8.2.2.
By Application
8.2.3. By Cancer Type
8.2.4. By Country
8.3. South America:
Country Analysis
8.3.1. Brazil Next Generation
Cancer Diagnostics Market Outlook
8.3.1.1.
Market Size & Forecast
8.3.1.1.1.
By Value
8.3.1.2.
Market Share & Forecast
8.3.1.2.1.
By Technology
8.3.1.2.2.
By Application
8.3.1.2.3.
By Cancer Type
8.3.2. Argentina Next
Generation Cancer Diagnostics Market Outlook
8.3.2.1.
Market Size & Forecast
8.3.2.1.1.
By Value
8.3.2.2.
Market Share & Forecast
8.3.2.2.1.
By Technology
8.3.2.2.2.
By Application
8.3.2.2.3.
By Cancer Type
8.3.3. Colombia Next
Generation Cancer Diagnostics Market Outlook
8.3.3.1.
Market Size & Forecast
8.3.3.1.1.
By Value
8.3.3.2.
Market Share & Forecast
8.3.3.2.1.
By Technology
8.3.3.2.2.
By Application
8.3.3.2.3.
By Cancer Type
9.
Middle East and Africa Next Generation Cancer Diagnostics
Market Outlook
9.1. Market Size &
Forecast
9.1.1. By Value
9.2. Market Share &
Forecast
9.2.1.
By Technology
9.2.2.
By Application
9.2.3. By Cancer Type
9.2.4. By Country
9.3. MEA: Country
Analysis
9.3.1. South Africa Next
Generation Cancer Diagnostics Market Outlook
9.3.1.1.
Market Size & Forecast
9.3.1.1.1.
By Value
9.3.1.2.
Market Share & Forecast
9.3.1.2.1.
By Technology
9.3.1.2.2.
By Application
9.3.1.2.3.
By Cancer Type
9.3.2. Saudi Arabia Next
Generation Cancer Diagnostics Market Outlook
9.3.2.1.
Market Size & Forecast
9.3.2.1.1.
By Value
9.3.2.2.
Market Share & Forecast
9.3.2.2.1.
By Technology
9.3.2.2.2.
By Application
9.3.2.2.3.
By Cancer Type
9.3.3. UAE Next Generation
Cancer Diagnostics Market Outlook
9.3.3.1.
Market Size & Forecast
9.3.3.1.1.
By Value
9.3.3.2.
Market Share & Forecast
9.3.3.2.1.
By Technology
9.3.3.2.2.
By Application
9.3.3.2.3.
By Cancer Type
9.3.4. Egypt Next
Generation Cancer Diagnostics Market Outlook
9.3.4.1.
Market Size & Forecast
9.3.4.1.1.
By Value
9.3.4.2.
Market Share & Forecast
9.3.4.2.1.
By Technology
9.3.4.2.2.
By Application
9.3.4.2.3.
By Cancer Type
10. Market Dynamics
10.1.
Drivers
10.2.
Challenges
11. Market Trends &
Developments
11.1.
Recent Developments
11.2.
Product Launches
11.3.
Mergers & Acquisitions
12. Global Next
Generation Cancer Diagnostics Market: SWOT Analysis
13.
Porter’s Five Forces Analysis
13.1.
Competition in the Industry
13.2.
Potential of New Entrants
13.3.
Power of Suppliers
13.4.
Power of Customers
13.5.
Threat of Substitute Product
14. Competitive
Landscape
14.1. GE HealthCare.
14.1.1.
Business Overview
14.1.2.
Company Snapshot
14.1.3.
Products & Services
14.1.4.
Financials (In case of listed)
14.1.5.
Recent Developments
14.1.6.
SWOT Analysis
14.2. Janssen Pharmaceuticals, Inc.
14.3. Illumina, Inc.
14.4. Novartis AG
14.5. F. Hoffmann-La Roche Ltd
14.6. Koninklijke Philips N.V.
14.7. QIAGEN
14.8. Agilent Technologies, Inc. (Dako)
14.9. Abbott Laboratories Inc.
14.10. Thermo Fisher Scientific Inc.
15. Strategic Recommendations
16. About
Us & Disclaimer